NasdaqGM:LGNDPharmaceuticals
Ligand Pharmaceuticals (LGND) Is Up 13.3% After Securing 9% Royalty on Newly Approved FILSPARI
Ligand Pharmaceuticals recently reported that its partner Travere Therapeutics received full FDA approval for FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric focal segmental glomerulosclerosis (FSGS) patients, the first and only approved treatment for this rare kidney disorder.
This approval secures a 9% royalty on worldwide FILSPARI sales for Ligand, potentially strengthening its high-margin royalty portfolio in a specialized nephrology market.
Next, we’ll examine how...